College of Pharmacy,University of Mustansiriyah discussed a master dissertation on preparing of new pharmaceutical compounds and testing their effectiveness in treating lung cancer by the postgraduate student, Mrs. Nour Al-Huda Dakhel Khalaf.

The dissertation aimed at preparing substituted derivatives of 2-thioxo-4-thiazolidinone compounds and diagnosing their molecular docking, as well as testing their biological effectiveness and comparing them to the anti-cancer drug erlotinib approved for the treatment of lung cancer.

The dissertation reviewed preparing new bi-substituted aminorodanine N-O derivatives based on the Schiff base reaction, resorting to the Knofenagel condensation method in two steps of reactions, identifying the compounds by measuring the melting point and conducting spectroscopic analyses, as well as analyzing the effect of the rhodanine derivatives in each reaction of lung cancer (A549) and normal cells (Hdfn) and compared its biological effectiveness with the drug (erlotinib), which has been approved as a standard for determining the activity of derivatives in cancer cells and toxicity, and their effects in normal cells.

The dissertation highlighted that the new compounds have excellent effectiveness in binding to and inhibiting the EGFR receptor, by establishing bonds mediated by hydrogen bonds with the amino acids that make up this receptor and that some of the compounds were more effective than the reference drug (erlotinib) and the strength of its binding, not to mention The new compounds showed high anti-cancer activity, along with low effect and high safety in normal cells.